Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.36 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.32 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24854368 | 1.00 | L3MBTL3 (0.36) | L3MBTL3L3MBTL1MBTD1HTR6TP53BP1 | |
| SCHEMBL12395781 | 1.00 | L3MBTL3 (0.36) | L3MBTL3L3MBTL1MBTD1HTR6TP53BP1 | |
| SCHEMBL15604163 | 0.98 | L3MBTL3 (0.35) | L3MBTL3L3MBTL1MBTD1HRH3SIGMAR1 | |
| SCHEMBL24854072 | 0.98 | L3MBTL3 (0.35) | L3MBTL3L3MBTL1MBTD1HRH3SIGMAR1 | |
| SCHEMBL11916115 | 0.98 | L3MBTL3 (0.35) | L3MBTL3L3MBTL1MBTD1HRH3SIGMAR1 | |
| SCHEMBL24854511 | 0.96 | L3MBTL3 (0.32) | L3MBTL3L3MBTL1SIGMAR1 | |
| SCHEMBL19669887 | 0.96 | L3MBTL3 (0.32) | L3MBTL3L3MBTL1SIGMAR1 | |
| SCHEMBL24854383 | 0.96 | L3MBTL3 (0.32) | L3MBTL3L3MBTL1SIGMAR1 | |
| SCHEMBL18369733 | 0.89 | HTR6 (0.35) | L3MBTL3L3MBTL1HTR6HRH3SIGMAR1 | |
| SCHEMBL18369779 | 0.89 | HTR6 (0.35) | L3MBTL3L3MBTL1HTR6HRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002382-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUNDS | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002382-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUNDS | KRAS, NRAS, HRAS | L3MBTL3 4752/4885L3MBTL1 4551/4885MBTD1 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.